Resveratrol improves motor function in patients with muscular dystrophies: an open-label, single-arm, phase IIa study

Abstract Muscular dystrophies (MDs) are inherited disorders characterized by progressive muscle weakness. Previously, we have shown that resveratrol (3,5,4′-trihydroxy-trans-stilbene), an antioxidant and an activator of the protein deacetylase SIRT1, decreases muscular and cardiac oxidative damage a...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Kentaro Kawamura, Shinobu Fukumura, Koki Nikaido, Nobutada Tachi, Naoki Kozuka, Tsugumi Seino, Kingya Hatakeyama, Mitsuru Mori, Yoichi M. Ito, Akiyoshi Takami, Shiro Hinotsu, Atsushi Kuno, Yukihiko Kawasaki, Yoshiyuki Horio, Hiroyuki Tsutsumi
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2020
Materias:
R
Q
Acceso en línea:https://doaj.org/article/bf548d12dece47e28717140c32a296ef
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:bf548d12dece47e28717140c32a296ef
record_format dspace
spelling oai:doaj.org-article:bf548d12dece47e28717140c32a296ef2021-12-02T12:33:53ZResveratrol improves motor function in patients with muscular dystrophies: an open-label, single-arm, phase IIa study10.1038/s41598-020-77197-62045-2322https://doaj.org/article/bf548d12dece47e28717140c32a296ef2020-11-01T00:00:00Zhttps://doi.org/10.1038/s41598-020-77197-6https://doaj.org/toc/2045-2322Abstract Muscular dystrophies (MDs) are inherited disorders characterized by progressive muscle weakness. Previously, we have shown that resveratrol (3,5,4′-trihydroxy-trans-stilbene), an antioxidant and an activator of the protein deacetylase SIRT1, decreases muscular and cardiac oxidative damage and improves pathophysiological conditions in animal MD models. To determine whether resveratrol provides therapeutic benefits to patients with MDs, an open-label, single-arm, phase IIa trial of resveratrol was conducted in 11 patients with Duchenne, Becker or Fukuyama MD. The daily dose of resveratrol was 500 mg/day, which was increased every 8 weeks to 1000 and then 1500 mg/day. Primary outcomes were motor function, evaluated by a motor function measure (MFM) scale, muscular strength, monitored with quantitative muscle testing (QMT), and serum creatine kinase (CK) levels. Adverse effects and tolerability were evaluated as secondary outcomes. Despite the advanced medical conditions of the patients, the mean MFM scores increased significantly from 34.6 to 38.4 after 24 weeks of medication. A twofold increase was found in the mean QMT scores of scapula elevation and shoulder abduction. Mean CK levels decreased considerably by 34%. Diarrhoea and abdominal pain was noted in six and three patients, respectively. Resveratrol may provide some benefit to MD patients.Kentaro KawamuraShinobu FukumuraKoki NikaidoNobutada TachiNaoki KozukaTsugumi SeinoKingya HatakeyamaMitsuru MoriYoichi M. ItoAkiyoshi TakamiShiro HinotsuAtsushi KunoYukihiko KawasakiYoshiyuki HorioHiroyuki TsutsumiNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 10, Iss 1, Pp 1-11 (2020)
institution DOAJ
collection DOAJ
language EN
topic Medicine
R
Science
Q
spellingShingle Medicine
R
Science
Q
Kentaro Kawamura
Shinobu Fukumura
Koki Nikaido
Nobutada Tachi
Naoki Kozuka
Tsugumi Seino
Kingya Hatakeyama
Mitsuru Mori
Yoichi M. Ito
Akiyoshi Takami
Shiro Hinotsu
Atsushi Kuno
Yukihiko Kawasaki
Yoshiyuki Horio
Hiroyuki Tsutsumi
Resveratrol improves motor function in patients with muscular dystrophies: an open-label, single-arm, phase IIa study
description Abstract Muscular dystrophies (MDs) are inherited disorders characterized by progressive muscle weakness. Previously, we have shown that resveratrol (3,5,4′-trihydroxy-trans-stilbene), an antioxidant and an activator of the protein deacetylase SIRT1, decreases muscular and cardiac oxidative damage and improves pathophysiological conditions in animal MD models. To determine whether resveratrol provides therapeutic benefits to patients with MDs, an open-label, single-arm, phase IIa trial of resveratrol was conducted in 11 patients with Duchenne, Becker or Fukuyama MD. The daily dose of resveratrol was 500 mg/day, which was increased every 8 weeks to 1000 and then 1500 mg/day. Primary outcomes were motor function, evaluated by a motor function measure (MFM) scale, muscular strength, monitored with quantitative muscle testing (QMT), and serum creatine kinase (CK) levels. Adverse effects and tolerability were evaluated as secondary outcomes. Despite the advanced medical conditions of the patients, the mean MFM scores increased significantly from 34.6 to 38.4 after 24 weeks of medication. A twofold increase was found in the mean QMT scores of scapula elevation and shoulder abduction. Mean CK levels decreased considerably by 34%. Diarrhoea and abdominal pain was noted in six and three patients, respectively. Resveratrol may provide some benefit to MD patients.
format article
author Kentaro Kawamura
Shinobu Fukumura
Koki Nikaido
Nobutada Tachi
Naoki Kozuka
Tsugumi Seino
Kingya Hatakeyama
Mitsuru Mori
Yoichi M. Ito
Akiyoshi Takami
Shiro Hinotsu
Atsushi Kuno
Yukihiko Kawasaki
Yoshiyuki Horio
Hiroyuki Tsutsumi
author_facet Kentaro Kawamura
Shinobu Fukumura
Koki Nikaido
Nobutada Tachi
Naoki Kozuka
Tsugumi Seino
Kingya Hatakeyama
Mitsuru Mori
Yoichi M. Ito
Akiyoshi Takami
Shiro Hinotsu
Atsushi Kuno
Yukihiko Kawasaki
Yoshiyuki Horio
Hiroyuki Tsutsumi
author_sort Kentaro Kawamura
title Resveratrol improves motor function in patients with muscular dystrophies: an open-label, single-arm, phase IIa study
title_short Resveratrol improves motor function in patients with muscular dystrophies: an open-label, single-arm, phase IIa study
title_full Resveratrol improves motor function in patients with muscular dystrophies: an open-label, single-arm, phase IIa study
title_fullStr Resveratrol improves motor function in patients with muscular dystrophies: an open-label, single-arm, phase IIa study
title_full_unstemmed Resveratrol improves motor function in patients with muscular dystrophies: an open-label, single-arm, phase IIa study
title_sort resveratrol improves motor function in patients with muscular dystrophies: an open-label, single-arm, phase iia study
publisher Nature Portfolio
publishDate 2020
url https://doaj.org/article/bf548d12dece47e28717140c32a296ef
work_keys_str_mv AT kentarokawamura resveratrolimprovesmotorfunctioninpatientswithmusculardystrophiesanopenlabelsinglearmphaseiiastudy
AT shinobufukumura resveratrolimprovesmotorfunctioninpatientswithmusculardystrophiesanopenlabelsinglearmphaseiiastudy
AT kokinikaido resveratrolimprovesmotorfunctioninpatientswithmusculardystrophiesanopenlabelsinglearmphaseiiastudy
AT nobutadatachi resveratrolimprovesmotorfunctioninpatientswithmusculardystrophiesanopenlabelsinglearmphaseiiastudy
AT naokikozuka resveratrolimprovesmotorfunctioninpatientswithmusculardystrophiesanopenlabelsinglearmphaseiiastudy
AT tsugumiseino resveratrolimprovesmotorfunctioninpatientswithmusculardystrophiesanopenlabelsinglearmphaseiiastudy
AT kingyahatakeyama resveratrolimprovesmotorfunctioninpatientswithmusculardystrophiesanopenlabelsinglearmphaseiiastudy
AT mitsurumori resveratrolimprovesmotorfunctioninpatientswithmusculardystrophiesanopenlabelsinglearmphaseiiastudy
AT yoichimito resveratrolimprovesmotorfunctioninpatientswithmusculardystrophiesanopenlabelsinglearmphaseiiastudy
AT akiyoshitakami resveratrolimprovesmotorfunctioninpatientswithmusculardystrophiesanopenlabelsinglearmphaseiiastudy
AT shirohinotsu resveratrolimprovesmotorfunctioninpatientswithmusculardystrophiesanopenlabelsinglearmphaseiiastudy
AT atsushikuno resveratrolimprovesmotorfunctioninpatientswithmusculardystrophiesanopenlabelsinglearmphaseiiastudy
AT yukihikokawasaki resveratrolimprovesmotorfunctioninpatientswithmusculardystrophiesanopenlabelsinglearmphaseiiastudy
AT yoshiyukihorio resveratrolimprovesmotorfunctioninpatientswithmusculardystrophiesanopenlabelsinglearmphaseiiastudy
AT hiroyukitsutsumi resveratrolimprovesmotorfunctioninpatientswithmusculardystrophiesanopenlabelsinglearmphaseiiastudy
_version_ 1718393882608140288